NCT06417099View on ClinicalTrials.gov

Efficacy of Dihydroartemisinin for Treating PCOS

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Dihydroartemisinin

dihydroartemisinin 40mg tid po for 90 consecutive days

Trial Locations (1)

200032

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06417099 - Efficacy of Dihydroartemisinin for Treating PCOS | Biotech Hunter | Biotech Hunter